Adeno-associated viruses (AAVs) are used in nearly a dozen FDA-approved therapies and more than 900 R&D projects to deliver therapeutic payloads to cells. Yet, large-scale AAV production is still a ...
Takeda is moving away from early-stage R&D work in adeno-associated virus-based gene therapies and the rare hematology spaces, with an unknown number of employees set to “transition out” of the pharma ...
Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback